Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis - Comparison with effects upon fatty acid amide hydrolase

Journal of Medicinal Chemistry

Volumn 50, Issue 20, 2007, Pages 5012-5023

  Cisneros, José Antonio ^a   Vandevoorde, Séverine ^b,c   Ortega Gutiérrez, Silvia ^a   Paris, Clément ^a   Fowler, Christopher J ^b   López Rodríguez, María L ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 OLEOYLGLYCEROL; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENZYME INHIBITOR; FATTY ACID AMIDASE; GLYCEROL DERIVATIVE; OXIRAN 2 YLMETHYLICOSA 5,8,11,14 TETRAENOATE; TETRAHYDRO 2H PYRAN 2 YLMETHYLICOSA 5,8,11,14 TETRAENOATE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; FATTY ACID METABOLISM; HYDROPHOBICITY; IC 50; LIPID HYDROLYSIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BRAIN; CELL LINE; CYTOSOL; EPOXY COMPOUNDS; GLYCERIDES; HYDROLYSIS; HYDROPHOBICITY; MEMBRANES; MICE; MONOACYLGLYCEROL LIPASES; MONOGLYCERIDES; POLYUNSATURATED ALKAMIDES; PYRANS; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34948835674     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070642y     Document Type: Article

References (53)

1. Di Marzo, V.; Petrosino, S. Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 2007, 18, 129-140.
2. Lambert, D. M.; Fowler, C. J. The endocannbinoid system: Drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48, 5059-5087.
3. Marsicano, G.; Lutz, B. Neuromodulatory functions of the endocannabinoid system. J. Endocrinol. Invest. 2006, 29, 27-46.
4. Marsicano, G.; Wotjak, C. T.; Azad, S. C.; Bisogno, T.; Rammes, G.; Cascio, M. G.; Hermann, H.; Tang, J.; Hofmann, C.; Zieglgänsberger, W.; Di Marzo, V.; Lutz, B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418, 530-534.
5. Lever, I. J.; Rice, A. S. Cannabinoids and pain. Handb. Exp. Pharmacol. 2007, 177, 265-306.
6. Pagotto, U.; Marsicano, G.; Cota, D.; Lutz, B.; Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 2006, 27, 73-100.
7. Centonze, D.; Finazzi-Agro, A.; Bernardi, G.; Maccarrone, M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci. 2007, 28, 180-187.
8. Karanian, D. A.; Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: Strategies for a wide array of disease states. Curr. Mol. Med. 2006, 6, 677-684.
9. Ortega-Gutiérrez, S.; Molina-Holgado, E.; Arévalo- Martín, A.; Correa, F.; Viso, A.; López-Rodríguez, M. L.; Di Marzo, V.; Guaza, C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J. 2005, 19, 1338-1340.
10. Bifulco, M.; Laezza, C.; Gazzerro, P.; Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion. Oncol. Rep. 2007, 17, 813-816.
11. Pacher, P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462.
12. Makara, J. K.; Mor, M.; Fegley, D.; Szabó, S. I.; Kathuria, S.; Astarita, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Rivara, S.; Freund, T. F.; Piomelli, D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signalling in hippocampus. Nat. Neurosci. 2005, 8, 1139-1141.
13. Szabo, B.; Urbanski, M. J.; Bisogno, T.; Di Marzo, V.; Mendiguren, A.; Baer, W. U.; Freiman, I. Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex in mediated by 2-arachidonoylglycerol. J. Physiol. 2006, 577, 263-280.
14. Hashimotodani, Y.; Ohno-Shosaku, T.; Kano, M. Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J. Neurosci. 2007, 27, 1211-1219.
15. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83-87.
16. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; Lichtman, A. H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 9371-9376.
17. Kathuria, S.; Gaetani, S.; Fegley, D.; Valiño, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9, 76-81.
18. Holt, S.; Comelli, F.; Costa, B.; Fowler, C. J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: Comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 2005, 146, 467-476.
19. Jayamanne, A.; Greenwood, R.; Mitchell, V. A.; Asian, S.; Piomelli, D.; Vaughan, C. W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 2006, 147, 281-288.
20. Goparaju, S. K.; Ueda, N.; Yamaguchi, H.; Yamamoto, S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 1998, 422, 69-73.
21. de Lago, E.; Petrosino, S.; Valenti, M.; Morera, E.; Ortega- Gutiérrez, S.; Fernández-Ruiz, J.; Di Marzo, V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem. Pharmacol. 2005, 70, 446-452.
22. Jhaveri, M. D.; Richardson, D.; Kendall, D. A.; Barrett, D. A.; Chapman, V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J. Neurosci. 2006, 26, 13318-13327.
23. Maione, S.; Bisogno, T.; de Novellis, V.; Palazzo, E.; Cristino, L.; Valenti, M.; Petrosino, S.; Guglielmotti, V.; Rossi, F.; Di Marzo, V. Elevation of endocannabinoid levels in the ventrolateral periaque-ductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 2006, 316, 969-982.
24. Lichtman, A. H.; Hawkins, E. G.; Griffin, G.; Cravatt, B. F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 2002, 302, 73-79.
25. Sugiura, T.; Kishimoto, S.; Oka, S.; Gokoh, M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 2006, 45, 405-446.
26. Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10819-10824.
27. Karlsson, M.; Contreras, J. A.; Hellman, U.; Tornqvist, H.; Holm, C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. J. Biol. Chem. 1997, 272, 27218-27223.
28. Viso, A.; Cisneros, J. A.; Ortega-Gutiérrez, S. The medicinal chemistry of agents targeting monoacylglycerol lipase. Curr. Top. Med. Chem. 2007, in press.
29. Cravatt, B. F.; Saghatelian, A.; Hawkins, E. G.; Clement, A. B.; Bracey, M. H.; Lichtman, A. H. Functional dissociation of the central and peripheral fatty acid amide signalling systems. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 10821-10826.
30. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002, 298, 1793-1796.
31. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimaraes, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem. 2005, 48, 1849-1856.
32. Alexander, J. P.; Cravatt, B. F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol. 2005, 12, 1179-1187.
33. Romero, F. A.; Du, W.; Hwang, I.; Rayl, T. J.; Kimball, F. S.; Leung, D.; Hoover, H. S.; Apodaca, R. L.; Breitenbucher, J. G.; Cravatt, B. F.; Boger, D. L. Potent and selective α-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. J. Med. Chem. 2007, 50, 1058-1068.
34. Saario, S. M.; Salo, O. M. H.; Nevalainen, T.; Poso, A.; Laitinen, J. T.; Järvinen, T.; Niemi, R. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Chem. Biol. 2005, 12, 649-656.
35. Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M. G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E. J.; Gangadharan, U.; Hobbs, C.; Di Marzo, V.; Doherty, P. Cloning of the first sn-1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell. Biol. 2003, 163, 463-468.
36. Dinh, T. P.; Kathuria, S.; Piomelli, D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol. 2004, 66, 1260-1264.
37. Goparaju, S. K.; Ueda, N.; Taniguchi, K.; Yamamoto, S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol. 1999, 57, 417-423.
38. Muccioli, G. G.; Xu, C.; Odah, E.; Cudaback, E.; Cisneros, J. A.; Lambert, D. M.; López-Rodríguez, M. L.; Bajjalieh, S.; Stella, N. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J. Neurosci. 2007, 27, 2883-2889.
39. Hohmann, A. G.; Suplita, R. L.; Bolton, N. M.; Neely, M. H.; Fegley, D.; Mangieri, R.; Krey, J. F.; Walker, J. M.; Holmes, P. V.; Crystal, J. D.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435, 1108-1112.
40. Holt, S.; Paylor, B.; Boldrup, L.; Alajakku, K.; Vandevoorde, S.; Sundström, A.; Cocco, M. T.; Onnis, V.; Fowler, C. J. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of Ibuprofen and indomethacin. Eur. J. Pharmacol. 2007, 565, 26-36.
41. Ghafouri, N.; Tiger, G.; Razdan, R. K.; Mahadevan, A.; Pertwee, R. G.; Martin, B. R.; Fowler, C. J. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br. J. Pharmacol. 2004, 143, 774-784.
42. Vandevoorde, S.; Saha, B.; Mahadevan, A.; Razdan, R. K.; Pertwee, R. G.; Martin, B. R.; Fowler, C. J. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 2005, 337, 104-109.
43. Fowler, C. J.; Tiger, G. Cyclooxygenation of the arachidonoyl side chain of 1-arachidonoylglycerol and related compounds block their ability to prevent anandamide and 2-oleoylglycerol metabolism by rat brain in vitro. Biochem. Pharmacol. 2005, 69, 1241-1245.
44. Saario, S. M.; Savinainen, J. R.; Laitinen, J. T.; Järvinen, T.; Niemi, R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 2004, 67, 1381-1387.
45. Vandevoorde, S.; Jonsson, K.-O.; Labar, G.; Persson, E.; Lambert, D. M.; Fowler, C. J. Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br. J. Pharmacol. 2007, 150, 186-191.
46. Makara, J. K.; Mor, M.; Fegley, D.; Szabo, S. I.; Kathuria, S.; Astarita, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Rivara, S.; Freund, T. T.; Piomelli, D. Corrigendum: Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signalling in hippocampus. Nat. Neurosci. 2007, 10, 134.
47. Saario, S. M.; Palomäki, V.; Lehtonen, M.; Nevalainen, T.; Järvinen, T.; Laitinen, J. T. URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem. Biol. 2006, 13, 811-814.
48. Jonsson, K.-O.; Vandevoorde, S.; Lambert, D. M.; Tiger, G.; Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 2001, 133, 1263-1275.
49. Thors, L.; Fowler, C. J. Is there a temperature-dependent uptake of anandamide into cells? Br. J. Pharmacol. 2006, 149, 73-81.
50. Vandevoorde, S.; Jonsson, K.-O.; Fowler, C. J.; Lambert, D. M. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J. Med. Chem. 2003, 46, 1440-1448.
51. Boldrup, L.; Wilson, S. J.; Barbier, A. J.; Fowler, C. J. A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J. Biochem. Biophys. Methods 2004, 60, 171-177.
52. Bisogno, T.; Cascio, M. G.; Saha, B.; Mahadevan, A.; Urbani, P.; Minassi, A.; Appendino, G.; Saturnino, C.; Martin, B.; Razdan, R.; Di Marzo, V. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim. Biophys. Acta 2006, 1761, 205-212.
53. López-Rodríguez, M. L.; Viso, A.; Ortega-Gutiérrez, S.; Fowler, C. J.; Tiger, G.; de Lago, E.; Fernández-Ruiz, J.; Ramos, J. A. Design, synthesis and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 2003, 46, 1512-1522.